Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Recommendation of “Hold” from Brokerages

Prestige Consumer Healthcare Inc. (NYSE:PBH) has been given an average recommendation of “Hold” by the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $94.80.

Several research firms have recently weighed in on PBH. Zacks Research downgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Thursday, September 4th. Wall Street Zen downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Sidoti raised shares of Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price target for the company in a research note on Wednesday, September 24th. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Wednesday. Finally, Canaccord Genuity Group reduced their price objective on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating for the company in a research note on Friday, August 8th.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock opened at $60.91 on Friday. The company has a 50 day moving average price of $65.27 and a 200-day moving average price of $76.14. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38. Prestige Consumer Healthcare has a fifty-two week low of $60.77 and a fifty-two week high of $90.04. The company has a market capitalization of $3.00 billion, a PE ratio of 14.30, a P/E/G ratio of 1.93 and a beta of 0.44.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing the consensus estimate of $1.01 by ($0.06). Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The company had revenue of $249.53 million for the quarter, compared to the consensus estimate of $260.71 million. During the same period in the prior year, the firm posted $0.90 EPS. The business’s revenue was down 6.6% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. As a group, equities analysts forecast that Prestige Consumer Healthcare will post 4.5 earnings per share for the current year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of large investors have recently bought and sold shares of the business. Kayne Anderson Rudnick Investment Management LLC raised its stake in Prestige Consumer Healthcare by 45.3% in the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,580,819 shares of the company’s stock worth $135,903,000 after buying an additional 493,199 shares in the last quarter. Geode Capital Management LLC raised its stake in Prestige Consumer Healthcare by 0.7% in the second quarter. Geode Capital Management LLC now owns 1,413,041 shares of the company’s stock worth $112,843,000 after buying an additional 9,455 shares in the last quarter. Invesco Ltd. raised its stake in Prestige Consumer Healthcare by 24.7% in the first quarter. Invesco Ltd. now owns 1,321,800 shares of the company’s stock worth $113,635,000 after buying an additional 261,537 shares in the last quarter. Congress Asset Management Co. raised its stake in Prestige Consumer Healthcare by 1.8% in the second quarter. Congress Asset Management Co. now owns 1,009,595 shares of the company’s stock worth $80,616,000 after buying an additional 18,015 shares in the last quarter. Finally, Westwood Holdings Group Inc. raised its stake in Prestige Consumer Healthcare by 2.4% in the second quarter. Westwood Holdings Group Inc. now owns 881,908 shares of the company’s stock worth $70,420,000 after buying an additional 20,626 shares in the last quarter. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.